Published in Hepatology on June 01, 2004
Factors influencing disease phenotype and penetrance in HFE haemochromatosis. Hum Genet (2010) 0.97
Prognostic factors and survival in patients with hereditary hemochromatosis and cirrhosis. Can J Gastroenterol (2006) 0.86
Function of the hemochromatosis protein HFE: Lessons from animal models. World J Gastroenterol (2008) 0.85
The diagnosis and management of hereditary haemochromatosis. Clin Biochem Rev (2010) 0.82
No hepatic iron overload 12 years after liver transplantation for hereditary hemochromatosis. Hepatology (2004) 0.80
Care of the liver transplant patient. Can J Gastroenterol Hepatol (2014) 0.77
Liver transplantation: an "in vivo" model for the pathophysiology of hemochromatosis? Hepatology (2004) 0.75
Is serum hepcidin causative in hemochromatosis? Novel analysis from a liver transplant with hemochromatosis. Can J Gastroenterol (2008) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med (2005) 7.18
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (2012) 6.93
Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med (2007) 6.11
Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med (2008) 5.43
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int (2008) 5.25
Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet (2003) 4.49
Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood (2004) 4.40
Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology (2003) 4.10
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology (2008) 3.82
Eosinophilic esophagitis in adults: clinical, endoscopic, histologic findings, and response to treatment with fluticasone propionate. Gastrointest Endosc (2006) 3.65
Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem (2005) 2.99
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology (2010) 2.81
Black cohosh and other herbal remedies associated with acute hepatitis. Med J Aust (2002) 2.54
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int (2005) 2.46
Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol (2009) 2.39
Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology (2007) 2.36
Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. J Hepatol (2012) 2.31
T lymphocytes interact with hepatocytes through fenestrations in murine liver sinusoidal endothelial cells. Hepatology (2006) 2.30
Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 2.28
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 2.17
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology (2004) 2.17
ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. Hepatology (2014) 2.12
Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med (2006) 2.11
Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology (2011) 2.05
The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial. Hepatology (2015) 2.04
Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology (2012) 1.96
CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver. J Hepatol (2012) 1.95
Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology (2002) 1.92
Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. Hepatology (2011) 1.89
Hepatocyte entry leads to degradation of autoreactive CD8 T cells. Proc Natl Acad Sci U S A (2011) 1.89
Acute liver failure associated with the use of herbal preparations containing black cohosh. Med J Aust (2003) 1.86
Fatal fulminant hepatic failure induced by a natural therapy containing kava. Med J Aust (2003) 1.84
HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology (2010) 1.76
CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol (2008) 1.62
Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. J Immunol (2010) 1.61
Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. J Hepatol (2006) 1.60
Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med (2006) 1.59
Postoperative ERCP versus laparoscopic choledochotomy for clearance of selected bile duct calculi: a randomized trial. Ann Surg (2005) 1.56
Serum ferritin concentration predicts mortality in patients awaiting liver transplantation. Hepatology (2010) 1.56
Approaching the promise of operational tolerance in clinical transplantation. Transplantation (2011) 1.54
Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology (2009) 1.54
The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. J Clin Invest (2004) 1.53
Early high peak hepatitis C viral load levels independently predict hepatitis C-related liver failure post-liver transplantation. Liver Transpl (2009) 1.50
Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology (2002) 1.50
Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology (2007) 1.49
Management of healthcare workers after occupational exposure to hepatitis C virus. Med J Aust (2003) 1.49
Relationships between blood levels of fat soluble vitamins and disease etiology and severity in adults awaiting liver transplantation. J Gastroenterol Hepatol (2011) 1.48
Naïve CD8 T cell activation by liver bone marrow-derived cells leads to a "neglected" IL-2low Bimhigh phenotype, poor CTL function and cell death. J Hepatol (2012) 1.48
Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis. Hepatology (2009) 1.47
Hereditary lysozyme amyloidosis: spontaneous hepatic rupture (15 years apart) in mother and daughter. role of emergency liver transplantation. Liver Transpl (2006) 1.46
Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology (2009) 1.44
Novel mutation in ferroportin1 is associated with autosomal dominant hemochromatosis. Blood (2002) 1.42
Insights into the pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene expression. Am J Pathol (2002) 1.34
The liver: a special case in transplantation tolerance. Semin Liver Dis (2007) 1.33
Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study. Hepatology (2012) 1.31
Pathogenesis and management of alcoholic hepatitis. J Gastroenterol Hepatol (2003) 1.28
A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology (2008) 1.27
Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology (2013) 1.26
A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology (2002) 1.26
Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology (2005) 1.25
The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J (2010) 1.24
Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology (2004) 1.24
Hepatopulmonary syndrome: update on recent advances in pathophysiology, investigation, and treatment. J Gastroenterol Hepatol (2013) 1.24
SMART amplification maintains representation of relative gene expression: quantitative validation by real time PCR and application to studies of alcoholic liver disease in primates. J Biochem Biophys Methods (2003) 1.23
Non-cirrhotic intrahepatic portal hypertension: associated gut diseases and prognostic factors. Dig Dis Sci (2010) 1.21
Predictors of relapse to harmful alcohol after orthotopic liver transplantation. Alcohol Alcohol (2006) 1.19
The role of cytokines and chemokines in the development of steatohepatitis. Semin Liver Dis (2007) 1.18
Relative importance of female-specific and non-female-specific effects on variation in iron stores between women. Br J Haematol (2003) 1.18
Hepcidin is down-regulated in alcoholic liver injury: implications for the pathogenesis of alcoholic liver disease. Alcohol Clin Exp Res (2006) 1.17
Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology (2005) 1.17
Altered Notch ligand expression in human liver disease: further evidence for a role of the Notch signaling pathway in hepatic neovascularization and biliary ductular defects. Am J Pathol (2002) 1.16
Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. J Hepatol (2007) 1.16
Role of primary intrahepatic T-cell activation in the 'liver tolerance effect'. Immunol Cell Biol (2002) 1.16
Common lymphatic endothelial and vascular endothelial receptor-1 mediates the transmigration of regulatory T cells across human hepatic sinusoidal endothelium. J Immunol (2011) 1.13
Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol (2006) 1.11
Intrahepatic immunity: a tale of two sites? Trends Immunol (2005) 1.11
Intrahepatic murine CD8 T-cell activation associates with a distinct phenotype leading to Bim-dependent death. Gastroenterology (2008) 1.11
Absence of Epstein-Barr virus DNA in the tumor cells of European hepatocellular carcinoma. Virology (2003) 1.10
Systemic viral infections and collateral damage in the liver. Am J Pathol (2006) 1.10
Carcinosarcoma of the biliary tract: two case reports and a review of the literature. Eur J Gastroenterol Hepatol (2005) 1.10
Upregulation of endogenous intrahepatic interferon stimulated genes during chronic hepatitis C virus infection. J Med Virol (2003) 1.09
Practical difficulties in the management of hepatitis B in the Asia-Pacific region. J Gastroenterol Hepatol (2004) 1.09
Intrahepatic gene expression in human alcoholic hepatitis. J Hepatol (2006) 1.08
Liver fibrosis: a balance of ACEs? Clin Sci (Lond) (2007) 1.08
Gene expression profiling of alcoholic liver disease in the baboon (Papio hamadryas) and human liver. Am J Pathol (2003) 1.08
Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci (2010) 1.07
Muscle mass and mortality in chronic liver disease: the impact of testosterone. Liver Transpl (2014) 1.07
HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. Hepatology (2009) 1.07